.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists have significantly advanced extracorporeal life support (ECLS) technology over recent decades. However, engineers still require further research to improve performance-efficiency, hemocompatibility, and long-term stability. Currently, many researchers evaluate early-stage devices under nonstandardized conditions. This makes it difficult to compare or translate data into clinical practice. To address this, an international expert group has established clear recommendations for ECLS device testing according to international norms.
Adopting these standardized protocols will represent a major advancement for the field. These criteria improve methodological consistency and ensure reproducibility across different research groups. Furthermore, the framework fosters a unified approach among clinicians and the medical device industry. By providing clear reporting guidelines, these protocols simplify the review of studies. Consequently, this common framework facilitates faster decision-making in the development and application of ECLS technologies.
Ultimately, these standards will help translate early-stage research into effective clinical tools. This unified methodology ensures that every technological improvement translates directly into better patient outcomes.
Early evaluations are often conducted under nonstandardized conditions, making it difficult to compare data across research groups or translate findings into clinical practice.
The protocols aim to improve methodological consistency, ensure reproducibility, and establish standardized criteria for reporting results in the medical device industry.
By providing a common framework, these standards make the review of studies more straightforward. This reduces the need for additional discussion on testing methods and speeds up decision-making.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. The information provided is based on current research and standardized protocols developed by international experts. Doctors and researchers should consult original source materials and the latest regulatory standards. Refer to the latest local and national guidelines for clinical practice.
References
1. Arens J et al. Standardization of In-Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development. ASAIO J. 2026 Apr 03. doi: 10.1097/MAT.0000000000002623. PMID: 41931830.
2. ELSO (Extracorporeal Life Support Organization). ELSO Guidelines for ECLS / ECMO Training and Centers. Ann Arbor, MI.
3. ISO 5840: Cardiovascular implants — Cardiac valve prostheses — Part 1: General requirements.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
International experts establish standardized in-vitro testing protocols for ECLS devices to improve research consistency, hemocompatibility, and clinical us...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
